“Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation” (2018) Farmeconomia. Health economics and therapeutic pathways, 19(1). doi:10.7175/fe.v19i1.1346.